Newsroom

Newsroom

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Literature
Read More

NeoGenomics Schedules its First Quarter Earnings Release for April 28, 2020

Press Release
Read More

Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression

Literature
Read More

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

Literature
Read More

Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer

Literature
Read More

NeoGenomics Announces Three-Year Contract to be Cornerstone Oncology and Cancer Testing Laboratory for Large, National Group Purchasing Organization

Press Release
Read More

NeoGenomics To Present At 41st Annual Raymond James Institutional Investor Conference

Press Release
Read More

NeoGenomics Reports 40% Revenue Growth to $107 Million in the Fourth Quarter

Press Release
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients